Previous Statements by INCY
» Incyte's CEO Bank of America Merrill Lynch 2012 Health Care Conference (Transcript)
» Incyte's CEO Discusses Q1 2012 Results - Earnings Call Transcript
» Incyte's Management Present at Barclays Capital 2012 Global Healthcare Conference (Transcript)
» Incyte Corporation's CEO Discusses Q4 2011 Results - Earnings Call Transcript
Pat AndrewsSo many of you have seen prior data on this particular compound as well as 424 and the data across RA patients has been very consistent. It’s a very potent JAK inhibitor; has a competitive profile and obviously looks very comparable to the data that’s been presented by Pfizer for tofacitinib. Our numbers are much smaller obviously so it’s early on. But it looks very promising it’s very encouraging; the data we presented on Friday in the late breaker session at ULR and then we hope later this year to show the six months data with Lilly, hopefully at ACR. And the next step would be to initiate the Phase III program and we also expect that to happen this year. Pam Murphy Maybe just flashing out some of the details, I mean clearly the efficacy side it seems that it is on the higher end of the ACR presented etcetera; on the appropriate doses it may look a little better than tofa at least in these early patients effects. On the same side, on the safety side I mean it seems like we saw a couple of things that we haven’t seen before like the creatinine increase on the drug. And so just want to get your thoughts of like you know do you think it’s possible to differentiate from tofa, from this week, like where do you think the differentiations will be eventually in the marketplace as the data holds out? Pat Andrews So I think that there will be a number of places that the products could differentiate; it’s a little bit difficult to say what all of them would be now, because they finished the Phase III and while we’ve seen quite a bit of data, we just have the Phase II data with a smaller number of patients. But some things that come to mind are very obvious such as 050 is a once-a-day drug versus tofa is a twice-a-day drug and 050 seems to not have many drug-to-drug interactions versus tofa had some and we have benefit from seeing the questions raised during the AdCom for tofa and there are some learnings from that that we could take in the design of the Phase III that should start later this year.
So all of those things I think give us the potential to have a differentiated product and we just have to see, we have to be further along with more patients before be able confident saying what they are, that 050 is JAK1, JAK2 inhibitor and the tofa product is more of an pan-JAK inhibitor. Therefore it has JAK3 that may play into. We’re not entirely sure what the value is of the JAK3 component on that and it may have some negatives to it.But again, all pre-mature. We are generally very pleased with the tofa AdCom. We thought it showed that the drug classes are good and viable, but at the same time left a room for some differentiation and some opportunities to maybe be stronger. Sapna Srivastava - Goldman Sachs I guess that ACR, this is a 24-week data. Do you have it in-house by now; I mean just for the feed two different sets of it, like, we’re seeing 12-week now at ULR or is it still…. Pat Andrews The trial is complete now, but you’ll just see the 12-week data here and the 24-week data, the 6-month data would be at ACR. Sapna Srivastava - Goldman Sachs And when can we expect to hear about the safety design, they’re just like from the tofa panel like when do we see the Phase III design of the trial start by the year-end…… Pat Andrews That’s the expectation, yes and that really would be a communication that Lilly would trigger, so until that point, we don’t have too much color we can provide on the Phase III, other than we know that Lilly is anxious to begin the Phase III trials which as we are. Sapna Srivastava - Goldman Sachs And just if we could, on that any questions from the audience on the RA drug? Read the rest of this transcript for free on seekingalpha.com